Marieke van Son

47 MRI-GUIDED ULTRAFOCAL HDR-BRACHYTHERAPY RESULTS Baseline characteristics Median age was 71 years (IQR 68-73). MRI prostatic volume was 40cc (32.3-41.7). Median PSA was 7.3 ng/ml (5.2-8.1) and median PSADT was 4.7 years (2.4-10.6). Radio- logical T-stage was T2a in 13 (43.3%), T2b in 4 (13.3%) and T2c in 13 (43.3%) patients. Gleason score was 3+3=6 in 16 (53.3%), 3+4=7 in 12 (40%) and 4+3=7 in 2 (6.7%) patients. Other baseline characteristics are shown in table 1. Table 1 – Baseline and treatment characteristics of the focal HDR-brachytherapy cohort Median / n IQR / % Unknown (%) Pre-treatment characteristics Age(years) 71 68-73 0 (0%) Biopsy technique TRUS-guided MRI-guided 13 1 43.3% 3.3% 16 (53.3%) Tumour location Base Midgland Apex Combination 2 13 8 7 6.7% 43.3% 26.7% 23.3% 0 (0%) Total number of cores 10 8-11 0 (0%) Number of positive cores 3 2-4 0 (0%) MRI volume prostate(cc) 40 32.3-41.7 0 (0%) Gleason score 3+3=6 3+4=7 4+3=7 16 12 2 53.3% 40% 6.7% 0 (0%) Clinical T-stage T1c T2a T2c 16 13 1 53.3% 43.3% 3.3% 0 (0%) Radiological T-stage T2a T2b T2c 13 4 13 43.3% 13.3% 43.3% 0 (0%) AJCC prognostic stage group Stage I Stage IIA Stage IIB Stage IIC 15 1 12 2 50% 3.3% 40% 6.7% 0 (0%) iPSA (ng/ml) 7.3 5.2-8.1 0 (0%) PSADT (months) 56.8 28.8-126.7 7 (23.3%) 3